MEI Pharma, Inc.
MEIP
$2.04
$0.042.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -96.73% | -50.66% | |||
| Gross Profit | 96.73% | 50.66% | |||
| SG&A Expenses | -33.82% | -15.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -57.14% | -33.20% | |||
| Operating Income | 57.14% | 33.20% | |||
| Income Before Tax | 66.57% | 56.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.57% | 56.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.57% | 56.50% | |||
| EBIT | 57.14% | 33.20% | |||
| EBITDA | 53.91% | 36.87% | |||
| EPS Basic | 66.56% | 56.50% | |||
| Normalized Basic EPS | 69.91% | 32.67% | |||
| EPS Diluted | 66.56% | 56.50% | |||
| Normalized Diluted EPS | 69.91% | 32.67% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||